References of "Philips, J. C"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrise en charge du diabete gestationnel.
Philips, J. C.; EMONTS, Patrick ULg; Pintiaux, Axelle ULg et al

in Revue medicale de Liege (2013), 68(9), 489-96

Pregnancy is associated with relative carbohydrate intolerance and insulin resistance. Gestational diabetes mellitus (GDM) is recognized as a risk factor for a number of adverse outcomes during pregnancy ... [more ▼]

Pregnancy is associated with relative carbohydrate intolerance and insulin resistance. Gestational diabetes mellitus (GDM) is recognized as a risk factor for a number of adverse outcomes during pregnancy, including excessive fetal growth, increased incidence of birth trauma and neonatal metabolic abnormalities. This recognition has led to recommendations to screen all pregnant women for GDM and to treat those whose glucose tolerance tests exceed threshold criteria. Numerous epidemiological studies show that GDM affects between 1 and 25% of pregnancies, depending on the ethnicity of the population studied and the diagnostic criteria. Intervention to change lifestyle and, if maternal hyperglycemia persists, treatment with additional oral medication or insulin injections have shown to improve perinatal outcomes. Patients with GDM have a high risk of developing type 2 diabetes in the years after delivery and these women are encouraged to practice specific health behaviours (dietary habits, physical activity) during the postpartum period. The present article discusses the management of GDM in the light of data from the latest studies and international recommendations. [less ▲]

Detailed reference viewed: 137 (15 ULg)
Full Text
Peer Reviewed
See detailLe traitement du diabète de type 2: entre insulinosensibilisateurs et insulinosécrétagogues
SCHEEN, André ULg; RADERMECKER, Régis ULg; Philips, J. C. et al

in Revue Médicale de Liège (2007), 62 Spec No

Type 2 diabetes is a complex disease characterized by a dual defect of insulin secretion and insulin sensitivity, which may vary from patient to patient, but also along the natural history of the disease ... [more ▼]

Type 2 diabetes is a complex disease characterized by a dual defect of insulin secretion and insulin sensitivity, which may vary from patient to patient, but also along the natural history of the disease in a particular patient. Besides the lifestyle changes, the treatment strategy comprises the administration of agents that promote insulin secretion and/or that improve insulin sensitivity. Drugs facilitating weight loss also improve glucose control by reducing insulin resistance. A global approach should be recommended to reduce the high cardiovascular risk of diabetic patients. The present article aims at summarizing our contribution to the development of drugs designed for the treatment of type 2 diabetes. [less ▲]

Detailed reference viewed: 672 (13 ULg)
Full Text
Peer Reviewed
See detailLe point sur les nouvelles insulines
Philips, J. C.; Radermecker, Régis ULg

in Revue Médicale Suisse (2005), 1(30), 1936-81940-1

It is well known that the optimal management of diabetes mellitus requires the use of various insulin formulations with complementary pharmacokinetics, in order to better mimic physiological (basal and ... [more ▼]

It is well known that the optimal management of diabetes mellitus requires the use of various insulin formulations with complementary pharmacokinetics, in order to better mimic physiological (basal and postprandial) insulin secretion. Recent advances led to the production of insulin analogues thanks to the substitution of specific amino acids. Pharmacokinetics is improved, without affecting pharmacodynamics or increasing side-effects. These new insulin forms concern both so-called ultra-short insulin analogues and long-acting insulin analogues (basal insulin). Even if they are not able to dramatically lower glycated haemoglobin levels, these new insulins significantly reduce the risk of hypoglycaemia and offer some practical advantages that could improve the quality of life of diabetic patients. [less ▲]

Detailed reference viewed: 35 (0 ULg)